Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy? | LLY Stock Analysis
1 extracted signal · 0 resolved · 1 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 26 Jun 2026, 11:45 UTC
- Recorded by Tahlil Plus
- 26 Jun 2026, 12:38 UTC
AI-generated source summary
Eli Lilly and Company (LLY) is showing strong financial performance driven by its successful development of weight-loss treatments and advancements in other therapeutic areas. The company's free cash flow and operating profit margins have shown significant growth, with operating profit margins increasing from 10% in 2017 to over 40% in the most recent fiscal year. The company's sales-to-cash flow ratio has been volatile but is generally strong. Eli Lilly's valuation, based on discounted cash flow models, is currently considered undervalued, with an estimated fair value of $1,442, compared to its market price of $1,114.58. This undervaluation is partly due to its low beta of 0.565, which suggests lower risk and less correlation with the broader market, making it an attractive component for portfolio diversification and risk reduction. The company's consistent research and development efforts, coupled with strong product pipeline, indicate continued growth potential.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.